1. AJ Rodriguez-Morales, JA Cardona-Ospina: Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis Travel medicine and Infectious Disease 2020 – Elsevier.

2. P Mehta, DF McAuley, M Brown, E Sanchez: COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet, 2020 - thelancet.com

3. Haruhiko Ogawa: The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome. Journal of thrombosis and haemostasis. First published: 17 April 2020

4. Ning Tang: Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy’ Journal of thrombosis and haemostasis. First published: 18 April 2020

5. Jean M. Connors and Jerrold H. Levy: Thromboinflammation and the hypercoagulability of COVID‐19. Journal of thrombosis and haemostasis. First published:19 April 2020

6. AnettaUndas et al.: Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Review Article. Blood. 2007 Mar 15; 109(6): 2285–2292

7. Buchanan MR, Hirsh J.: Effect of aspirin on hemostasis and thrombosis. N Engl Reg Allergy Proc. 1986 Jan-Feb; 7 (1):26-31.

8. Ignasi Rodríguez-Pintó et al.: The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients Rheumatology, Volume 57, Issue 7, July 2018, Pages 1264–1270, 11 April 2018

9. NICE COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19

10. Batya Swift Yasgur: More Evidence Hydroxychloroquine Is Ineffective, Harmful in COVID-19 May 22, 2020 Medscape Thursday, May 28, 2020April 29, 2020

11. Colette DeJong, MD1; Robert M. Wachter: The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19—First, Do No Harm. JAMA Intern Med. Published online April 29, 2020. doi:10.1001/jamainternmed.2020.1853 ORIGINAL ARTICLE

12. Bin Cao et al.: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 May 7, 2020 N Engl J Med 2020; 382:1787-1799 DOI: 10.1056/NEJMoa2001282 March 24, 2020

13. Neil M. Ampel et al.: Lopinavir-Ritonavir Was Not Effective for COVID-19 N Engl J Med 2020 Mar 18 Baden LR and Rubin EJ. N Engl J Med 2020 Mar 18

14. Silverman, Adam Feuerstein, and Matthew Herper: New data on Gilead’s remdesivir show no benefit for coronavirus patients. APRIL 23, 2020.

15. ClinicalTrials.gov Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19) (CORON-ACT) Sponsor: University Hospital Inselspital, Berne Information provided by (Responsible Party): University Hospital Inselspital, Berne. ClinicalTrials.gov Identifier: NCT04335071 April 6, 2020

16. Ziegler CGK et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. DOI: 10.1016/j.cell.2020.04.035

17. L. Bielory: Clinical complications of heterologous antisera administration. Journal of Wilderness Medicine 2, 127-139 (1991) Division of Allergy & Immunology, UMDNJ - New Jersey Medical School.

18. Jairo Victoria Ch.: Ivermectina nuevos usos de una vieja droga; revisión. Revista Asociación Colombiana de Dermatología y Cirugía Dermatológica. Volumen 7, número 1, febrero de 1999.

19. Leon Caly; Julian D.Druce; Mike G.Catton; David A.Jans; Kylie M.Wagstaff The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research 3 April 2020

20. Wagstaff. K: Possible coronavirus drug identified by Monash University scientists 03 April 2020https://doi.org/10.1016/j.antiviral.2020.104787

21. Carvallo, Héctor; Hirsch, Roberto; Fajardo, Francisco; Ciruzzi, Juan M.; y Martín, Mirta: Ivermectina, corticoides, aspirina y enoxaparina en el tratamiento del covid 19. Revista Científica Multidisciplinaria del Hospital A. A. Eurnekián. Edicion especial nro. 5 covid-19 (abril 2020) pp16-27.

22. Hirsch, Roberto; Nacucchio, Marcelo; Cassará, María L.; Ghirardi, Patricio; y Carvallo, Héctor E.: Ivermectina su utilidad en profilaxis, terapéutica e inmunidad contra el covid 19. Revista Científica Multidisciplinaria del Hospital A. A. Eurnekián. Edicion especial nro. 6 covid-19 pp. 2-42 (Mayo 2020).

23. Carvallo, Héctor; Hirsch, Roberto; Fajardo, Francisco; Ciruzzi, Juan; y Martín Mirta: Iver- mectina, corticoides, aspirina y enoxaparina en COVID 19. Rev. Educándonos. Arch. Arg. Derm. 2020; 7 (2): 40-42.

24. Li Wen et al: TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie Volume 142, November 2017, Pages 1-10https://doi.org/10.1016/j.biochi.2017.07.016Get rights and content

25. Dmitry Stepanov y Peter Lierz: Bromhexine Hydrochloride: Potential Approach to Prevent or Treat Early Stage COVID-19. Frenxiv Papers, DOI: 10.31226/osf.io/j4ut2, April 2020 

26. Markus Depfenhart et al: Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?InternEmerg Med. 2020 May 26: 1–12. doi: 10.1007/s11739-020-02383-3 [Epub ahead of print] PMCID: PMC7249615 PMID: 32458206

27. Solomon Habtemariam et al: Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2. Pharmacol Res. 2020 Jul; 157: 104853. 2020 Apr 30. doi: 10.1016/j.phrs.2020.104853 PMCID: PMC7192109 PMID: 32360584

Para descargar el PDF del artículo
Bromhexina. Un paso más en la estrategia terapéutica contra COVID-19

Haga click aquí